Thanks to the power of vaccines, more and more children in poor countries are growing up healthier, enabling them to spend more time at school and giving them the chance of a healthy, productive life.

The GAVI Alliance exists to redress global inequities in access to new and underused vaccines. Since 2000, with generous support from donors and strong commitment from countries, we have helped to immunise an additional 440 million children which will save 6 million lives.

As a public-private partnership, our Alliance represents all the key stakeholders in global immunisation: implementing and donor governments, the World Health Organization, UNICEF, the World Bank, the Bill & Melinda Gates Foundation, civil society, the vaccine industry and private companies.

Drawing on the individual strengths of its members, the GAVI Alliance model aggregates country demand, guarantees long-term, predictable funding and brings down prices, helping to ensure that generations of children in poor countries do not miss out on life-saving, economy-boosting vaccines.

Our funding supports 11 vaccines, including those against pneumococcal disease and rotavirus, the leading vaccine-preventable causes of pneumonia and diarrhoea, and human papillomavirus, which causes cervical cancer.

Healthy children with a healthy future

Immunisation is one of the best investments we can make in future generations.
Delivering results

Since 2000:

440 million children immunised
equivalent to combined populations of USA + UK + France

6 million lives saved
equivalent to total annual births in USA + UK + France

- GAVI Alliance support has helped to catalyse an extraordinary surge in vaccine introductions, bringing global immunisation rates to unprecedented levels.
- Since the five-in-one pentavalent vaccine was launched in 2001, 72 of the 73 countries eligible for GAVI Alliance support have introduced the vaccine into their routine immunisation programmes, with the 73rd introduction scheduled in South Sudan later this year.
- From January 2011 to December 2013, our Alliance has supported a record number of country introductions of pneumococcal vaccine and rotavirus vaccine – protecting against pneumonia and diarrhoea, two of the biggest killers of children.
- In 2013, the GAVI Alliance started to support two more vaccines: the human papillomavirus (HPV) vaccine against cervical cancer, one of the largest cancer killers of women; and the combined measles-rubella vaccine, a 2-in-1 shot against the causes of congenital abnormalities and early deaths.
- Increased investments in vaccines have transformed the global vaccine market, attracting new suppliers of quality vaccines at sustainable prices. In 2001, five vaccine manufacturers were supplying vaccines to the GAVI Alliance, with just one based in a middle-income country; by the end of 2013, this number had grown to 12, of which five are based in middle-income countries.
- By 2015, our Alliance will have helped to immunise half a billion additional children since its foundation in 2000.
- From 2010 to 2012, the GAVI Alliance secured a 35% reduction in the total vaccine cost of immunising a child with pentavalent, pneumococcal and rotavirus vaccines.

Reduced vaccine prices

<table>
<thead>
<tr>
<th>Year</th>
<th>Baseline</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$ 35</td>
<td>US$ 33</td>
<td>US$ 23</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: UNICEF Supply Division, 2013

- With support from the UK Government and the Bill & Melinda Gates Foundation, the GAVI Matching Fund initiative has attracted 12 private sector partners and raised more than US$ 150 million in cash and in kind.

1 Vaccinations administered with GAVI Alliance support from 2000 to 2013 are estimated to avert six million deaths over the lifetimes of vaccinated children.
The opportunity within our reach

We urgently need to build upon this momentum as 1.5 million children under five still die every year from vaccine-preventable diseases in the world’s poorest countries. As we approach 2015 and despite significant progress, many countries need to intensify their efforts to meet Millennium Development Goal 4, which aims to reduce under-5 mortality by two thirds.

2020 vision

We stand at a critical moment in time where we can dramatically accelerate progress achieved against the leading killers of children and women. With bold new commitments from donors, implementing countries, vaccine manufacturers and the private sector, coupled with the power of immunisation, our Alliance has the potential to:

- Reach one billion children by the early 2020s;
- Nearly double the number of lives saved since GAVI was founded;
- Unlock over 100 billion dollars in economic benefits through health care savings and productivity gains.

On 20 May 2014, the GAVI Alliance is launching its second replenishment. We want to ensure that we do not miss this tremendous opportunity to reach even more children in poor countries with life-saving vaccines and help lay the foundations for sustainable development.

At a high-level meeting hosted by the European Commission, we will present the economic and public health impact that our Alliance can make over the period 2016–2020 and explain to donors the financial resources needed to turn hope into reality for hundreds of millions of children, their parents and their communities.

Sustainable development

We believe that all development must be sustainable. The GAVI Alliance aims to be catalytic and help countries towards self-sufficiency.

As countries become more prosperous, GAVI Alliance support starts phasing out. By 2020, twenty countries will have taken over full financing of their immunisation programmes.
21st century development model

By bringing the key stakeholders in global immunisation together around a single mission, the GAVI Alliance combines the technical expertise of the development community with the business know-how of the private sector.

Efficiency
Nothing illustrates the power of our 21st century development model more than the Alliance’s ability to bring together the key players in the vaccine market to coordinate existing systems, create synergies and avoid duplicating activities.

Long-term funding commitment
Donor governments set the virtuous cycle in motion by making long-term commitments to support the GAVI Alliance’s programmes, either as direct contributions or through the International Finance Facility for Immunisation (IFFIm) and the Advance Market Commitment.

Sustainability
Together with donor governments, developing countries are also stepping up investment in their routine immunisation programmes, leading to healthier and more productive populations. As national prosperity grows, countries scale up investment in their own immunisation programmes, eventually “graduating” from GAVI Alliance support.

Affordability: more health for money
The availability of long-term, predictable funding for immunisation coupled with aggregated demand enables manufacturers to supply vaccines at more affordable prices. There is also a significant opportunity to enhance the role of other private sector partners. This is achieved through additional cash contributions and leveraging their expertise to address our key challenges such as modernising the supply chain and improving data for decision-making.

GAVI Alliance and the Millennium Development Goals
Vaccines provide health and economic benefits that contribute to the Millennium Development Goals (MDGs). By keeping children healthy, vaccines help to break a cycle of poverty and ill health. The GAVI Alliance’s mission supports countries to accelerate progress towards MDG 4, which aims to reduce child mortality. The Alliance is also contributing to MDG 8, to develop a global partnership for development.

An investment in future generations

Vaccines help people live longer and have healthier lives, but their impact does not end there. Research shows that spending on childhood vaccination programmes also contributes to national economic growth and poverty reduction.

In 2012, some of the leading experts on health economics ranked childhood immunisation as one of the three most cost-effective solutions to advance global welfare.
They estimated that spending approximately US$ 1 billion annually on expanded immunisation coverage would prevent 1 million child deaths per year. Put into economic terms, the benefits would be 20 times greater than the cost.

Investing in the GAVI Alliance will not only save millions of lives through vaccine programmes but also provide tens of billions of dollars in economic benefits for poor countries.

© The Measles Initiative/C. McNab